Englerin A Rewires Phosphosignaling via Hsp27 Hyperphosphorylation to Induce Cytotoxicity in Renal Cancer Cells.
Suat Peng NeoAsfa Alli-ShaikSheena WeeZijie LimJayantha GunaratnePublished in: Journal of proteome research (2022)
Englerin A (EA) is a small-molecule natural product with selective cytotoxicity against renal cancer cells. EA has been shown to induce apoptosis and cell death through cell-cycle arrest and/or insulin signaling pathways. However, its biological mode of action or targets in renal cancer remains enigmatic. In this study, we employed advanced mass spectrometry-based phosphoproteomics approaches to identify EA's functional roles in renal cancer. We identified 10,940 phosphorylation sites, of which 706 sites exhibited EA-dependent phosphorylation changes. Integrated analysis of motifs and interaction networks suggested activation of stress-activated kinases including p38 upon EA treatment. Of note, a downstream target of p38, Hsp27, was found to be hyperphosphorylated on multiple sites upon EA treatment. Among these, a novel site Ser65 on Hsp27, which was further validated by targeted proteomics, was shown to be crucial for EA-induced cytotoxicity in renal cancer cells. Taken together, these data reveal the complex signaling cascade that is induced upon EA treatment and importantly provide insights into its effects on downstream molecular signaling.
Keyphrases
- cell death
- cell cycle arrest
- mass spectrometry
- small molecule
- heat shock protein
- papillary thyroid
- type diabetes
- heat stress
- signaling pathway
- pi k akt
- oxidative stress
- squamous cell carcinoma
- diabetic rats
- epithelial mesenchymal transition
- gene expression
- liquid chromatography
- squamous cell
- metabolic syndrome
- high resolution
- electronic health record
- endoplasmic reticulum stress
- drug induced
- insulin resistance
- drug delivery
- high performance liquid chromatography
- young adults
- deep learning
- capillary electrophoresis
- skeletal muscle
- lymph node metastasis
- artificial intelligence
- childhood cancer